#USA #Philadelphia #Berger Montague #Novo Nordisk #Hims & Hers

Berger Montague Launches Investigation into Hims & Hers Health Inc.

Date: September 19, 2025
Location: Philadelphia

In a significant move for shareholders of Hims & Hers Health Inc. (NYSE: HIMS), Berger Montague, a reputable national securities litigation law firm, has initiated an investigation into potential breaches of fiduciary duties by the company’s Board of Directors. This inquiry comes in light of Novo Nordisk A/S’s recent decision to terminate its partnership with Hims & Hers, raising critical questions about the Board’s oversight and governance practices.

The investigation by Berger Montague is primarily concerned with how the Board managed the partnership with Novo Nordisk, especially as they face allegations of deceptive marketing practices related to unapproved compounded versions of semaglutide. This came after Novo Nordisk formally announced that it would end its collaboration with Hims & Hers in June 2025, citing concerns over the company’s marketing strategies and compliance with regulations of their pharmacological products.

The implications of this termination are profound, potentially impacting shareholder value and the company’s reputation in the health and wellness sector. As a firm that has been at the forefront of securities class-action litigation since 1970, Berger Montague has a long-standing history of advocating for investors' rights and holding companies accountable for misconduct.

For the shareholders of Hims & Hers, the stakes are high. This investigation aims to determine if the Board acted in the best interests of the investors and whether they failed to manage their fiduciary responsibilities adequately. In an environment where transparency and accountability are critical to investor confidence, this situation raises significant alarms.

Shareholders looking for more information about the investigation can reach out directly to Berger Montague’s legal team, which includes Radha Raghavan and Andrew Abramowitz, both of whom can be contacted via email or telephone. They are dedicated to uncovering the truth about the Board's actions and ensuring that the rights of shareholders are upheld.

Given Berger Montague’s extensive expertise in securities law, this inquiry could potentially lead to further actions against Hims & Hers’ Board if substantial evidence of wrongdoings is uncovered. It underscores the importance of accountability and ethical governance in health-related public companies, which are often scrutinized for their marketing and operational practices.

As the investigation unfolds, stakeholders in the health and wellness sectors will undoubtedly be watching closely. The outcome could not only influence Hims & Hers’ future but also serves as a critical reminder for all corporations about the indispensable value of maintaining ethical standards and integrity in their business practices.

In summary, Berger Montague's investigation signifies a pivotal moment for both Hims & Hers Health Inc. and its shareholders. It raises fundamental questions about fiduciary duties, the management of partnerships, and the overarching need for transparency and trust in corporate governance. Shareholders must remain vigilant and informed as further developments arise from this significant legal inquiry.